Serum amyloid A (SAA) is an acute-phase protein widely used as a biomarker for inflammation, infection, and disease monitoring. Accurate laboratory measurement of SAA is essential for clinical decision-making, yet assay variability between platforms remains a challenge. This study evaluated the analytical performance of a new SAA chemistry analyzer assay and compared its results against an established reference method.
The researchers assessed key analytical parameters, including precision, linearity, detection limits, and carryover. The new assay demonstrated high reproducibility, with coefficients of variation consistently within acceptable limits. Its linear measurement range was broad enough to cover both low-grade and high-level inflammatory states. Detection limits were low, making it suitable for identifying even minor inflammatory activity. The assay showed no significant carryover, ensuring reliability during high-throughput testing.
When compared with a reference method, the new assay demonstrated strong correlation and agreement, confirming its clinical comparability. Minor discrepancies were noted at extremely high concentrations, but these did not affect clinical interpretation in most cases. Additionally, the assay’s fast turnaround time and adaptability to automated platforms highlighted its practicality for routine laboratory settings.
Overall, the findings suggest that this new SAA assay is both analytically robust and clinically reliable. Its strong agreement with established methods supports its adoption in routine diagnostics, particularly in settings where rapid, large-scale SAA testing is needed to guide patient management.
LabMed Discovery
Experimental study
Evaluation of the performance of a new serum amyloid A chemiluminescence immunoassay
20-Aug-2025